WolverHeme Happy Hour
By Bernard Marini, Anthony Perissinotti, et al.
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 3
Reviews: 0
Episodes: 47
Description
Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks!
Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
| Episode | Date |
|---|---|
|
Spring Cleaning the Evidence from ASH 2025 with Common Sense Oncology
|
Apr 13, 2026 |
|
HLH: From Chaos to Clarity... and Back to Chaos!
|
Mar 20, 2026 |
|
An Exercise in Uncertainty with Jonathan Gluck
|
Feb 10, 2026 |
|
ASH Leukemia Review: the more we learn, the less we know!
|
Dec 17, 2025 |
|
RIP 7+3 (1973-2025)? Why PARADIGM Doesn't Deliver the Eulogy
|
Dec 09, 2025 |
|
MajesTEC-3 and ASH 2025: Let's get "TEC"nical
|
Nov 25, 2025 |
|
Episode 40: Coffee and Community Hematology
|
Oct 24, 2025 |
|
Chill For 5: The Febrile Neutropenia Survival Guide
|
Oct 09, 2025 |
|
Episode 38: Prophy and Pints!
|
Sep 10, 2025 |
|
Episode 37: Spilling Drinks over Cytarabine Dosing
|
Jul 11, 2025 |
|
Episode 36: ODAC - Our Decisions Are Confusing
|
May 28, 2025 |
|
CSO Encore Video Presentation - SWOG1826 & STARGLO Trials Critically Examined
|
May 05, 2025 |
|
Dex and the Cytokine City: Managing CRS with Bispecifics
|
Apr 07, 2025 |
|
LFGooo! The Rise, the Fall, and the Resurrection of Gemtuzumab in AML
|
Mar 11, 2025 |
|
Episode 32: Navigating a BlinatumoMAD World
|
Jan 21, 2025 |
|
The Aquila Study: Blowing Hot Air or a Soaring Success for Smoldering Multiple Myeloma
|
Jan 15, 2025 |
|
Pour Decisions, or ASH-olutely Fabulous? Reviewing 2024 ASH Lymphoma Updates
|
Dec 24, 2024 |
|
A Bunch of ASHholes Discuss Myeloma Abstracts
|
Nov 16, 2024 |
|
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
|
Nov 08, 2024 |
|
Episode 27: Mantle Cell Masterclass with Tycel Phillips
|
Oct 10, 2024 |
|
Houston, we don't have a problem... with APOLLO
|
Aug 28, 2024 |
|
From Ancient Remedies to Modern Miracles: The Evolution of APL Treatment
|
Jun 13, 2024 |
|
Episode 24: Myeloma Madness with the Myeloma Man
|
Apr 17, 2024 |
|
Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
|
Jan 25, 2024 |
|
LymphOMG: Pouring Over Lymphoma Abstracts from ASH
|
Dec 29, 2023 |
|
AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy
|
Dec 19, 2023 |
|
ASH Pregaming - Myeloma Madness with Manni and Papa Heme
|
Dec 01, 2023 |
|
AML Maintenance Part 2: a metaMORPHOsis?
|
Nov 08, 2023 |
|
AML Maintenance Part 1: Set Your QUAZARs to Stun
|
Oct 25, 2023 |
|
Episode 17: The Hemophilia Eras Tour
|
Aug 23, 2023 |
|
Common Sense Oncology: Outcomes That Matter
|
Aug 01, 2023 |
|
All too well: the reality of leukemia treatment
|
Jun 08, 2023 |
|
Episode 14: A Quantum Leap in AML Treatment? Dissecting Quizartinib Data with Dr. Dale Bixby
|
May 09, 2023 |
|
Episode 13: You get blinatumomab! You get blinatumomab!
|
Feb 24, 2023 |
|
Episode 12: Tinder for T Cells - Bispecifics in DLBCL
|
Feb 08, 2023 |
|
Episode 11: "Olu the Drunk Snowman" - IDH inhibitors in R/R AML with Dr. Jill Lykon
|
Jan 21, 2023 |
|
Episode 10: ASH Recap Part 2 - Papa Heme + WolverHeme
|
Dec 21, 2022 |
|
Episode 9: ASH Recap Part 1 - Dauno-Double Trouble
|
Dec 14, 2022 |
|
Episode 8: Pulling the Goalie on FLT3 Inhibitor Use in AML - A Discussion with Dr. Dale Bixby
|
Nov 23, 2022 |
|
Episode (3+)7: Straight Outta Roswell - OG AML Data
|
Oct 07, 2022 |
|
Episode 6: Dr. StrangeDrug or: How I Learned to Stop Worrying and Love the Asparaginase
|
Jul 21, 2022 |
|
Episode 5: IDH Inhibitors in AML: not so AGILE
|
Jun 03, 2022 |
|
Episode 4: All Aboard the Oncology StewardSHIP
|
May 27, 2022 |
|
Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
|
Apr 22, 2022 |
|
Episode 3.1: History of Acute Lymphoblastic Leukemia Treatment and Building the BFM Backbone
|
Apr 22, 2022 |
|
Episode 2: We Don't Talk About Rylaze
|
Mar 18, 2022 |
|
Episode 1: Surrogate Endpoints in AML
|
Mar 11, 2022 |